Asthika Goonewardene
Stock Analyst at Truist Securities
(2.16)
# 2,932
Out of 5,182 analysts
89
Total ratings
41.86%
Success rate
-3.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $134 → $120 | $115.07 | +4.28% | 6 | Feb 24, 2026 | |
| ZYME Zymeworks | Initiates: Buy | $40 | $28.56 | +40.06% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $30.33 | +41.77% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $26.64 | +80.18% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $127.75 | +13.50% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $24.95 | +56.31% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $15.23 | +556.60% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $131.67 | -24.81% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $44.65 | +9.74% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $102.06 | +51.87% | 3 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $88 → $71 | $23.65 | +200.21% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.25 | +344.44% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.42 | +604.23% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $3.43 | +337.32% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $22.12 | +58.23% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $33.59 | +346.56% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.92 | +36.99% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $2.13 | +792.02% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $7.93 | +5,347.67% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.13 | +1,376.01% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $0.99 | +5,960.61% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $9.62 | +1,771.10% | 4 | Aug 23, 2022 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $134 → $120
Current: $115.07
Upside: +4.28%
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $28.56
Upside: +40.06%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $30.33
Upside: +41.77%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $26.64
Upside: +80.18%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $127.75
Upside: +13.50%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $24.95
Upside: +56.31%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $15.23
Upside: +556.60%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $131.67
Upside: -24.81%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $44.65
Upside: +9.74%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $102.06
Upside: +51.87%
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $23.65
Upside: +200.21%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.25
Upside: +344.44%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.42
Upside: +604.23%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.43
Upside: +337.32%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $22.12
Upside: +58.23%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $33.59
Upside: +346.56%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.92
Upside: +36.99%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $2.13
Upside: +792.02%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $7.93
Upside: +5,347.67%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.13
Upside: +1,376.01%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $0.99
Upside: +5,960.61%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $9.62
Upside: +1,771.10%